Table 1 Clinical and demographic characteristics and the outcome of patients with COVID-19

Age^c

58.87 ± 14.1

 Female^a

39 (22.3%)

 Male^a

136 (77.7%)

Comorbidity^a

96 (54.9%)

 DM^a

63 (36%)

 HTN^a

63 (36%)

 IHD^a

8 (4.6%)

 Malignancy^a

7 (4%)

 Renal disease^a

13 (7.43%)

Severe/critical^a

67 (38.3%)

Oxygen use^a

110 (62.9%)

 Standard oxygen^a

91 (52%)

 HFNC^a

32 (18.3%)

 NIV^a

15 (8.6%)

 IMV^a

36 (20.6%)

 TLC (× 10³/μl)^b

10.6 (7.3–15.1)

 Lymphocyte (/μl)^b

1485 (1044–2190)

 HB (g/dl)^c

13.187 ± 1.932

 PLT (× 10³/μl)^b

302 (227–387)

 AST (U/l)^b

44 (31–70)

 ALT (U/l)^b

54 (34–90)

 Urea (mg/dl)^b

54 (41–101)

 Creatine (mg/dl)^b

1 (0.9–1.5)

 d-dimer (μg/ml)^b

1008 (523–2963)

 Ferritin (ng/ml)^b

1036 (546–2332)

 CRP (mg/l)^b

92.8 (41.8–196.2)

Respiratory co-infection^a

19 (10.9%)

In-hospital mortality^a

34 (19.4%)